All In Biotech

Drug Trial Radar · NCT05537142

A Study to Assess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic Impairment

A Phase I, Open-label, Single-center, Single-dose, Parallel Group Study to Evaluate the Pharmacokinetics of BV100 in Participants with Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Healthy Control Participants

Last checked: Nov 19, 2026Latest source record: Jan 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

33

Actual

Start

Sep 2, 2022

Primary completion

Jul 30, 2024

Study completion Oct 30, 2024

Sponsor

Lead sponsor
BioVersys AGIndustry
Sponsor type
Industry
Collaborators
Clinical Research Units Hungary
First posted
Sep 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To investigate the pharmacokinetics (PK) of rifabutin in subjects with hepatic impairment after single intravenous (IV) infusion of BV100

Conditions

  • Healthy Participants

Interventions

  • BV100Drug

    Rifabutin for Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To investigate the pharmacokinetics (PK) of rifabutin in participants with hepatic impairmentTime frame: 15 days
  2. To characterize the single dose pharmacokinetic profile of rifabutinTime frame: 15 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CRU Hungary Kft., Early Phase Unit

    Kistarcsa, Hungary

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.